

Serum Exchange #549

February 3, 2016

The results for **Serum Exchange 549 (sera 1189 - 1192)**, are summarized in Tables 32-38 and individual laboratory results by method are listed

in Tables 39-50. Sera strongly positive to A2, A19, and A29 were examined in this study.

Sample 1189 was reported to be strongly positive to A2 by all methods. In addition, reactivity to A28 (A68 and A69) and a number of 5C specificities, including B17 (B57 and B58), was detected by various methods. Luminex and ELISA also reported strong reactivity to A32, B13, and 1C specificities. Additional strong reactivity to a number of C-locus specificities (Cw2, Cw4, Cw5, Cw6, Cw15, Cw17, and Cw18) was also reported by Luminex. For

class II, reactivity to DR9 was reported by Luminex, Luminex PRA, and 1 NIH-extended lab. Additional reactivity to a number of DQ specificities (DQ4, DQ5, DQ6, DQ8, DQ9), as well as reactivity to DR1 and DR4, was detected by Luminex and Luminex PRA. In addition, Luminex reported strong anti-DR53 and -DR7 reactivity. Allele level reactivity to DQA1*01 and DQA1*03 was also reported by Luminex.

1189	method	#labs	A2	A68	A69	A28	B57	B58	B17	B62	B35	B53	B72	B50	B63	A24	A25	B45	B46	B49	B71	B75	B52	B51	B13
class I	NIH-Std	4	100			25			25	25							25								
	NIH-Ext	2	100	50	50		50																		
	AHG	3	67	67	33		33	33	33	33				33	33	33									
	Luminex	25	100	100	100		96	96		84	96	96	96	100	96	92	48	84	96	96	96	96	92	88	88
	Flow	1	no specificities assigned																						
	ELISA	2	100	100	100		100	100		100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
	C1q	1	no consensus																						
	Other	2	50	50	50		50	50		50	50	50	50												

1189	method	#labs	B78	B56	B18	A3	A32	A29	A11	A23	Cw15	Cw17	Cw18	Cw4	Cw6	Cw2	Cw5	B76	B77	B55	A31	A74	B44	B15	
	NIH-Ext	2			50																				
	AHG	3		33																				33	
	Luminex	25	88	92	44	88	88	80	76	72	100	100	100	100	100	100	96	96	96	92	88	88	84		
	Flow	1	no specificities assigned																						
	ELISA	2	100			100	100	100	100	100															

1189	method	#labs	DQ4	DQ5	DQ6	DQ8	DQ9	DR1	DR4	DR9	DR53	DR7	DR14	DR10	DQ7	DQ2	DR15	DR51
class II	NIH-Ext	1	no consensus															
	Luminex	20	100	90	100	95	95	100	100	100	95	90	60	25	25	20	15	15
	Flow	1	no specificities assigned															
	C1q	1	no consensus															
	Other	2	50	50	50	50	50	50	50	50								

1190	method	#labs	A2	A68	A69	A28	B57	B58	B17	B18	B27	B2708	B37	B63	B65	B49	B50	B51	B35	B44	B45	B52	B13	B62	B64	B72	B53	B78	B59	B47	B46	B38	B54	B55	B56	B71	B39	B67	B75	B76	B77	B82	A24		
class I	NIH-Std	4	100			25			25																																				
	NIH-Ext	2	100	50	50		50																																						
	AHG	3	100	100	33	33	67	67	33	33	33		33	33	33																														
	Luminex	25	100	100	100		100	100		100	96	44	96	84	88	96	96	96	96	96	96	92	92	92	88	88	88	88	84	88	84	84	80	96	96	96	92	88	88	88	88	88	68	60	
	Flow	1	no specificities assigned																																										
	ELISA	2	100	100	100		100	100		100	100		100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100														
	C1q	1	no consensus																																										
	Other	2	50	50				50																																					

1190	method	#labs	DR11	DR52	DR13	DR14	DR17	DR18	DQ2	DR12	DP14	DP17	DP18	DP28	DPw2	DPw3	DR7	DP10	DP20	DP9	DPw6	DPw4	DP402
class II	NIH-STD	1	no consensus																				
	NIH-Ext	1	no specificities assigned																				
	Luminex	11	100	100	100	100	95	89	95		100	100	100	100	100	100	100	89	89	89	89	74	45
	Flow	1	no specificities assigned																				
	C1q	1	no consensus																				
	Other	2	50	50	50	50	50	50	50	50													

For **sample 1190**, strong anti-A2 reactivity was reported by all methods. Additional reactivity to A28 (A68 and A69) and B17 (B57 and B58) was reported by various methods. Luminex and ELISA also detected strong reactivity to B44, B45, as well as to a number of 5C, 7C, and 8C specificities. Anti-DR11 reactivity was reported for this sample by Luminex, Luminex PRA, and 1 NIH-standard lab. In addition, DR13, DR14, DR17, DR18, DR52, and DQ2 reactivity was reported by Luminex and Luminex PRA. Strong reactivity to a number of DP antigens was also reported by Luminex.

Sample 1191 was found to be strongly positive to A31 and A30. Additional reactivity to A29 and number of 10C specificities was reported by various methods. Strong class II reactivity was detected for this sample, as Luminex and Luminex PRA reported strong anti-DQ7, -DR7, -DR8. -DR9, -DR11, -DR12, -DR13, -DR14, -DR17, -DR18, -DR52 reactivity. Weak DQ2 and DQ4 reactivity was also reported. Additional reactivity to a number of DP antigens, as well as to DQA1*04, DQA1*05, DQA1*06, and DPA1*01, was also detected by Luminex.

1191	method	#labs	A31	A30	A29	A33	A25	A26	A66	A6601	A6602	A34	A74	A32	A24	A2403	A80	B8	A43	A23	B45	B57	B58	B37	A68	A1	A2	A34		
class I	NIH-Std	4	100	50	50		50	50							50										50		50			
	NIH-Ext	2	100	100																										
	AHG	3	100	100		67							33																	
	Luminex	25	100	100	100	100	96	96	80	32	32	100	96	96	20	8	8	28	96	88	20	20	20	12						
	Flow	1	no specificities assigned																											
	ELISA	2	100	100	100	50	50	50	50				100	50			50	100								50		50		
	C1q	1	no consensus																											
	Other	2	50	50	50	50	50	50	50			50			50															

1191	method	#labs	DR7	DR8	DR9	DR11	DR12	DR13	DR14	DR17	DR18	DR52	DQ7	DQ2	DQ4	DP17	DP18	DP28	DPw2	DPw4	DP15	DP19	DP20	DP23	DPw3	DP11	DPw1	DP13	DPw6	DQ6	DP401	DP402
class II	NIH-Ext	1	no specificities assigned																													
	Luminex	19	100	100	100	100	100	100	100	95	95	100	100	37	26	100	100	95	89	89	84	74	74	74	58	47	42	42	42	42	21	21
	Flow	1	no specificities assigned																													
	C1q	1	no consensus																													
	Other	2	50	50	50	50	50	50	50	50	50	50	50	50	50																	

For **sample 1192**, strong reactivity to A29 was detected by all methods. In addition, reactivity to 1C and 10C specificities, as well as reactivity to some 7C specificities, was reported by various methods. For class II, Luminex and Luminex PRA reported reactivity to DR7, DR9, DQ4, DQ7, DQ8, and DQ9.

Additional reactivity to a number of DP antigens, as well as allele level reactivity to DQA1*02:01, DPA1*02:01, and DPA1*02:02, was reported by Luminex.

1192	method	#labs	A29	A30	A31	A26	A33	A1	A80	A74	A66	A6601	A34	A10	B42	A36	A3	A11	B7	B55	B81	B35
class I	NIH-Std	3	67																			
	NIH-Ext	2	100	50																		
	AHG	3	100	67	33	67	33	33	33	67	33	33		33								
	Luminex	25	96	100	100	96	100	96	96	92	80	28	100		72	96	96	72	88	72	64	50
	Flow	1	no specificities assigned																			
	ELISA	2	100	50	50	100	50	50	50	100	50	50	50		50	50	50	50	50	50	50	
	C1q	1	no consensus																			
	Other	2	50			50									50							50
1192	method	#labs	B54	A43	A1101	A1102	B67	B56	B82	A6602	B27	B48	B8101	B2708	B60	B8201	A25	B41	B51	B52	B63	
	AHG	3															33					
	Luminex	25	20	100	24	24	72	56	48	32	20	20	12	8	8	8						
	Other	2	50															50	50	50	50	

1192	method	#labs	DR7	DR9	DQ7	DQ8	DQ9	DQ4	DPw1	DPw5	DP19	DP14	DP13	DP9	DP11	DP17	DQ2	DP10	DPw3	DPw6	DR18	DP18	DP401	DPw4	DP15	DP20
class II	NIH-Ext	1	no consensus																							
	Luminex	8	100	100	95	95	95	90	85	85	80	75	75	70	60	60	60	55	55	45	25	25	20	20	15	15
	Flow	1	no specificities assigned																							
	C1q	1	no consensus																							
	Other	2	50	50	50	50	50	50																		

NEXT MAILING DATE: March 2, 2016
Arlene Locke, David Gjertson, Qiheng Zhang, and Elaine F. Reed

Table 32. Summary of the 549th Serum Exchange (Serum #1189-1192) by NIH-Standard and NIH-Extended - class I

Method: NIH-Standard											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
4 typing Labs			4 typing Labs			4 typing Labs			3 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	100%	100%	A2	100%	36%	A31	100%	67%	A29	67%	43%
A25	25%	100%	A28	25%	100%	A30	50%	67%			
A28	25%	100%	B17	25%	100%	A25	25%	100%			
B17	25%	100%	B8	25%	100%	A68	25%	67%			
B62	25%	100%				A24	25%	50%			
						A26	25%	50%			
						A2	25%	43%			
						A29	25%	25%			

Method: NIH-Extended											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	100%	95%	A2	100%	95%	A30	100%	100%	A29	100%	67%
A68	50%	100%	A68	50%	100%	A31	100%	86%	A30	50%	40%
A69	50%	100%	A69	50%	100%						
B18	50%	100%	B57	50%	100%						
B57	50%	100%									

Table 33. Summary of the 549th Serum Exchange (Serum #1189-1192) by Antiglobulin, C1q, and Other - class I

Method: Antiglobulin											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
3 typing Labs			3 typing Labs			3 typing Labs			3 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	67%	100%	A2	100%	100%	A30	100%	100%	A29	100%	100%
A68	67%	89%	A68	100%	89%	A31	100%	100%	A26	67%	90%
A69	33%	100%	B57	67%	100%	A33	67%	100%	A30	67%	64%
B15	33%	100%	B58	67%	100%	A74	33%	100%	A74	67%	42%
B17	33%	100%	A28	33%	100%				A10	33%	100%
B50	33%	100%	A69	33%	100%				A31	33%	100%
B56	33%	100%	B17	33%	100%				A66	33%	100%
B57	33%	100%	B37	33%	100%				A6601	33%	100%
B58	33%	100%	B63	33%	100%				A80	33%	100%
B62	33%	100%	B65	33%	100%				A33	33%	75%
B63	33%	100%	B18	33%	86%				A1	33%	67%
A24	33%	86%	B27	33%	80%				A25	33%	50%

Method: C1q											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Method: Other											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	50%	100%	A2	50%	100%	A25	50%	100%	A26	50%	100%
A68	50%	100%	A68	50%	100%	A26	50%	100%	A29	50%	100%
A69	50%	100%	B58	50%	100%	A29	50%	100%	B35	50%	100%
B35	50%	100%				A30	50%	100%	B41	50%	100%
B53	50%	100%				A31	50%	100%	B42	50%	100%
B57	50%	100%				A32	50%	100%	B51	50%	100%
B58	50%	100%				A33	50%	100%	B52	50%	100%
B62	50%	100%				A34	50%	100%	B53	50%	100%
B72	50%	100%				A66	50%	100%	B54	50%	100%

Table 34. Summary of the 549th Serum Exchange (Serum #1189-1192) by Luminex - class I

*** Serum 1189 ***		
25 typing Labs		
Antigen	Consensus	Inclusion
A2	100%	100%
A68	100%	100%
A69	100%	100%
B50	100%	100%
CW15	100%	100%
CW17	100%	100%
CW18	100%	100%
CW4	100%	100%
CW6	100%	100%
CW2	100%	88%
B35	96%	100%
B46	96%	100%
B49	96%	100%
B53	96%	100%
B57	96%	100%
B58	96%	100%
B63	96%	100%
B71	96%	100%
B72	96%	100%
B75	96%	100%
B76	96%	100%
B77	96%	100%
CW5	96%	50%
B52	92%	100%
B55	92%	100%
B56	92%	100%
A24	92%	75%
A3	88%	100%
A31	88%	100%
A32	88%	100%
A74	88%	100%
B13	88%	100%
B51	88%	100%
B78	88%	100%
B45	84%	100%

*** Serum 1190 ***		
25 typing Labs		
Antigen	Consensus	Inclusion
A2	100%	100%
A68	100%	100%
A69	100%	100%
B57	100%	100%
B58	100%	100%
B18	100%	67%
B50	96%	100%
B55	96%	100%
B27	96%	86%
B51	96%	86%
B37	96%	75%
B49	96%	75%
B54	96%	75%
B35	96%	67%
B56	96%	60%
B44	96%	50%
B52	92%	100%
B71	92%	75%
B13	92%	71%
B45	92%	67%
B39	88%	100%
B62	88%	100%
B64	88%	100%
B65	88%	100%
B67	88%	100%
B72	88%	100%
B75	88%	100%
B76	88%	100%
B77	88%	100%
B53	88%	67%
B59	88%	33%
B46	84%	100%
B78	84%	100%
B47	84%	50%
B63	84%	50%

*** Serum 1191 ***		
25 typing Labs		
Antigen	Consensus	Inclusion
A29	100%	100%
A30	100%	100%
A31	100%	100%
A33	100%	100%
A34	100%	100%
A26	96%	100%
A32	96%	100%
A43	96%	100%
A74	96%	100%
A25	96%	67%
A23	88%	100%
A66	80%	100%
A6601	32%	100%
A6602	32%	100%
B8	28%	100%
A24	20%	100%
B45	20%	100%
B57	20%	100%
B58	20%	100%
B37	12%	100%
A2403	8%	100%
A80	8%	100%

*** Serum 1192 ***		
25 typing Labs		
Antigen	Consensus	Inclusion
A30	100%	100%
A31	100%	100%
A33	100%	100%
A34	100%	100%
A43	100%	100%
A1	96%	100%
A26	96%	100%
A29	96%	100%
A36	96%	100%
A3	96%	67%
A80	96%	67%
A74	92%	100%
B7	88%	100%
A66	80%	100%
B42	72%	100%
B55	72%	100%
B67	72%	100%
A11	72%	50%
B81	64%	100%
B56	56%	100%
B82	48%	100%
A6602	32%	100%
A6601	28%	100%
A1101	24%	100%
A1102	24%	100%
B27	20%	100%
B48	20%	100%
B54	20%	100%
B8101	12%	100%
B2708	8%	100%
B60	8%	100%
B8201	8%	100%

Table 35. Summary of the 549th Serum Exchange (Serum #1189-1192) by Flow Cytometry and ELISA - class I

Method: Flow Cytometry											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Method: ELISA											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	100%	100%	A2	100%	100%	A29	100%	100%	A26	100%	100%
A68	100%	100%	A68	100%	100%	A30	100%	100%	A29	100%	100%
A69	100%	100%	A69	100%	100%	A31	100%	100%	A74	100%	100%
B13	100%	100%	B13	100%	100%	A74	100%	100%	A1	50%	100%
B35	100%	100%	B18	100%	100%	B8	100%	100%	A11	50%	100%
B46	100%	100%	B35	100%	100%	A1	50%	100%	A3	50%	100%
B49	100%	100%	B37	100%	100%	A25	50%	100%	A31	50%	100%
B50	100%	100%	B44	100%	100%	A26	50%	100%	A33	50%	100%
B53	100%	100%	B45	100%	100%	A32	50%	100%	A34	50%	100%
B57	100%	100%	B57	100%	100%	A33	50%	100%	A36	50%	100%
B58	100%	100%	B58	100%	100%	A34	50%	100%	A66	50%	100%
B62	100%	100%	B59	100%	100%	A66	50%	100%	A6601	50%	100%
B63	100%	100%	B63	100%	100%	A80	50%	100%	A80	50%	100%
B71	100%	100%	B65	100%	100%				B42	50%	100%
B72	100%	100%	B72	100%	100%				B55	50%	100%
B75	100%	100%	B78	100%	100%				B7	50%	100%
B78	100%	100%	B27	100%	75%				B81	50%	100%
A11	100%	75%	B51	100%	75%				A30	50%	50%
B45	100%	75%	B53	100%	75%						
B51	100%	75%	B62	100%	75%						
B52	100%	75%	B64	100%	75%						
A3	100%	65%	B38	50%	100%						
A23	50%	100%	B46	50%	100%						
A24	50%	100%	B47	50%	100%						
A25	50%	100%	B49	50%	100%						
A29	50%	100%	B50	50%	100%						
A32	50%	100%	B52	50%	100%						

Table 36. Summary of the 549th Serum Exchange (Serum #1189-1192) by NIH and Flow Cytometry - class II

Method: NIH-Standard											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
NT			no consensus			NT			NT		

Method: NIH-Extended											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no antigens assigned			no antigens assigned			no consensus		

Method: Flow Cytometry											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no antigens assigned			no antigens assigned			no antigens assigned			no antigens assigned		

Table 37. Summary of the 549th Serum Exchange (Serum #1189-1192) by C1q and Other - class II

Method: C1q											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Method: Other											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
DQ4	50%	100%	DQ2	50%	100%	DQ2	50%	100%	DQ4	50%	100%
DQ5	50%	100%	DR11	50%	100%	DQ4	50%	100%	DQ7	50%	100%
DQ6	50%	100%	DR12	50%	100%	DQ7	50%	100%	DQ8	50%	100%
DQ8	50%	100%	DR13	50%	100%	DR11	50%	100%	DQ9	50%	100%
DQ9	50%	100%	DR14	50%	100%	DR12	50%	100%	DR7	50%	100%
DR1	50%	100%	DR17	50%	100%	DR13	50%	100%	DR9	50%	100%
DR4	50%	100%	DR18	50%	100%	DR14	50%	100%			
DR9	50%	100%	DR52	50%	100%	DR17	50%	100%			
						DR18	50%	100%			
						DR52	50%	100%			
						DR7	50%	100%			
						DR8	50%	100%			
						DR9	50%	100%			

Table 38. Summary of the 549th Serum Exchange (Serum #1189-1192) by Luminex - class II

*** Serum 1189 ***		
20 typing Labs		
Antigen	Consensus	Inclusion
DQ6	100%	100%
DR1	100%	100%
DR4	100%	100%
DR9	100%	86%
DQ4	100%	73%
DQ8	95%	100%
DQ9	95%	100%
DR53	95%	82%
DQ5	90%	78%
DR7	90%	50%
DR14	60%	100%
DR10	25%	100%
DQ7	25%	20%
DQ2	20%	20%
DR15	15%	100%
DR51	15%	100%
DQ3	5%	100%

*** Serum 1190 ***		
19 typing Labs		
Antigen	Consensus	Inclusion
DP14	100%	100%
DP17	100%	100%
DP18	100%	100%
DP28	100%	100%
DPW2	100%	100%
DPW3	100%	100%
DR11	100%	100%
DR13	100%	100%
DR14	100%	100%
DR52	100%	100%
DR7	100%	100%
DR17	95%	100%
DQ2	95%	90%
DP10	89%	100%
DP20	89%	100%
DP9	89%	100%
DPW6	89%	100%
DR18	89%	100%
DPW4	74%	87%
DP402	45%	100%
DQ7	5%	100%
DR3	5%	100%

*** Serum 1191 ***		
19 typing Labs		
Antigen	Consensus	Inclusion
DP17	100%	100%
DP18	100%	100%
DQ7	100%	100%
DR11	100%	100%
DR12	100%	100%
DR13	100%	100%
DR14	100%	100%
DR52	100%	100%
DR7	100%	100%
DR8	100%	100%
DR9	100%	100%
DP28	95%	100%
DR17	95%	100%
DR18	95%	100%
DPW2	89%	100%
DPW4	89%	100%
DP15	84%	100%
DP19	74%	100%
DP20	74%	100%
DP23	74%	100%
DPW3	58%	86%
DP11	47%	100%
DPW1	42%	92%
DP13	42%	60%
DPW6	42%	50%
DQ2	37%	40%
DQ6	26%	100%
DQ4	26%	25%
DP401	21%	100%
DP402	21%	100%
DP14	5%	100%
DQ5	5%	100%
DR1404	5%	100%
DR15	5%	100%
DR3	5%	100%

*** Serum 1192 ***		
20 typing Labs		
Antigen	Consensus	Inclusion
DR7	100%	100%
DR9	100%	100%
DQ7	95%	100%
DQ8	95%	100%
DQ9	95%	100%
DQ4	90%	75%
DPW1	85%	100%
DPW5	85%	100%
DP19	80%	100%
DP14	75%	100%
DP13	75%	67%
DP9	70%	100%
DP11	60%	100%
DP17	60%	100%
DQ2	60%	40%
DP10	55%	100%
DPW3	55%	33%
DPW6	45%	50%
DR18	25%	100%
DP18	25%	33%
DP401	20%	100%
DPW4	20%	100%
DP15	15%	100%
DP20	15%	100%
DP28	10%	100%
DR11	10%	100%
DR13	10%	100%
DP23	5%	100%
DQ3	5%	100%
DR12	5%	100%
DR14	5%	100%
DR17	5%	100%
DR4	5%	100%
DR53	5%	100%
DR8	5%	100%

Table 39. Individual laboratory results for Serum #1189-1192 by NIH-Standard and NIH-Extended - class I

	**** Serum 1189 ****						**** Serum 1190 ****						**** Serum 1191 ****				**** Serum 1192 ****				
Investigator	% POS	A2	A28	B17	B62	Other	% POS	A2	A28	B17	B8	Other	% POS	A31	A30	Other	% POS	A29	Other	Method	
Claas, F.H.J.	50	+			+	A25	75	+			+		49	+		A24,A2,A25,A26 >	4			STD	
Thornton, Alycia		+						+						+		A29				STD	
Vasilescu, Rodica	61	+	+	+			33	+	+	+			25	+	+		17	+		STD	
Watson, Narelle	52	+					26	+					15	+	+		4	+		STD	

	**** Serum 1189 ****						**** Serum 1190 ****						**** Serum 1191 ****				**** Serum 1192 ****				
Investigator	% POS	A2	A68	A69	B18	Other	% POS	A2	A68	A69	B57	Other	% POS	A30	A31	Other	% POS	A29	A30	Other	Method
Lardy, N.M.	43	+			+	B57	39	+					20	+	+		7	+	+		EXT
Reed, Elaine F. PhD	46	+	+	+			44	+	+	+	+		32	+	+		9	+			EXT

Table 40. Individual laboratory results for Serum #1189-1192 by Antiglobulin and C1q - class I

Investigator	**** Serum 1189 ****											**** Serum 1190 ****											**** Serum 1191 ****						**** Serum 1192 ****										Method		
	% POS	A2	A68	A69	B15	B17	B50	B56	B57	B58	Other	% POS	A2	A68	B57	B58	A28	A69	B17	B37	B63	Other	% POS	A30	A31	A33	A74	Other	% POS	A29	A26	A30	A74	A10	A31	A66	A6601	A80		Other	
Cecka, J. Michael P	97											78	+	+	+	+	+				+	B18	35	+	+	+	+			50	+	+	+	+		+	+	+	+	A25>	Antiglobulin
Hahn, Amy B. PhD		+	+				+	+	+	+	A24>		+	+	+	+				+		B27>		+	+					+	+	+	+				+		A1>	Antiglobulin	
Vasilescu, Rodica	60	+	+	+	+	+						50	+	+				+	+				22	+	+	+			20	+					+					Antiglobulin	

Investigator	**** Serum 1189 ****											**** Serum 1190 ****											**** Serum 1191 ****						**** Serum 1192 ****										Method			
	% POS	A2	A68	A69							Other	% POS	A2									Other	% POS	A29	A30	A31	A33	A74	Other	% POS	A26	A29	A30	A43							Other	
Phelan, Donna L.		+	+	+								+												+	+	+	+	+			+	+	+	+								C1q

Table 41. Individual laboratory results for Serum #1189-1192 by Other - class I

Investigator	**** Serum 1189 ****											**** Serum 1190 ****											Method	
	% POS	A2	A68	A69	B35	B53	B57	B58	B62	B72	B75	Other	% POS	A2	A68	B58								Other
Phelan, Donna L.	100												95											Other
Reed, Elaine F. PhD	94	+	+	+	+	+	+	+	+	+	+		84	+	+	+								Other

Investigator	**** Serum 1191 ****											**** Serum 1192 ****											Method	
	% POS	A25	A26	A29	A30	A31	A32	A33	A34	A66	A74	Other	% POS	A26	A29	B35	B41	B42	B51	B52	B53	B54		B60
Phelan, Donna L.	58												82											Other
Reed, Elaine F. PhD	66	+	+	+	+	+	+	+	+	+	+		84	+	+	+	+	+	+	+	+	+	+	B78,B62,B7,B71 >

Other = Luminex PRA

Table 42. Individual laboratory results for Serum #1189 by Luminex - class I

		**** Serum 1189 ****																																											
Investigator	% POS	A2	A68	A69	B50	CW15	CW17	CW18	CW4	CW6	CW2	B35	B46	B49	B53	B57	B58	B63	B71	B72	B75	B76	B77	CW5	B52	B55	B56	A24	A3	A31	A32	A74	B13	B51	B78	B45	B62	B44	A29	Other	Method				
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A203,A2403 >	LMX		
Bengochea, Carrette	56	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,A34,A23,A43 >	LMX		
Cecka, J. Michael P	85	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B67	LMX		
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B48,B47,B27 >	LMX		
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A203,B60,B61 >	LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B27,B54,B67 >	LMX	
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A66,B47,B27 >	LMX	
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B27,B67,A34 >	LMX	
Hamdi, Nuha	82	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B27,B67,A34 >	LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B60,B61,B48 >	LMX	
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX	
Libyh/Roulin, Taban	69	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B27,B54,B67 >	LMX	
Loewenthal , Ron M	49	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B15	LMX		
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B48,A66,B47 >	LMX	
McCoy, Heather	40	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX		
Pancoska, Carol Ph	70	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B27,B67,A34 >	LMX	
Permpikul, Vejbaesy	51	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,CW12	LMX	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A66,B27,B54 >	LMX	
Pule, Ziningi	46	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B15,A66,B27 >	LMX	
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A66,B47,B27 >	LMX	
Rosen-Bronson, Sa		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B48,A66,B47 >	LMX	
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A34,A23,B2708	LMX	
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A203,B48,B47 >	LMX	
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B60,B61,B48 >	LMX	
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B61,B48,A66 >	LMX

Table 44. Individual laboratory results for Serum #1191 by Luminex - class I

Investigator	**** Serum 1191 ****																	Method							
	% POS	A29	A30	A31	A33	A34	A26	A32	A43	A74	A25	A23	A66	A6601	A6602	B8	A24		B45	B57	B58	B37	Other		
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+										LMX
Bengochea, Carrette	19	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		+	+			A2403	LMX	
Cecka, J. Michael P	56	+	+	+	+	+	+	+	+	+	+	+	+	+	+									LMX	
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+									LMX	
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+					LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+									LMX	
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+			+		+				+		LMX	
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Hamdi, Nuha	56	+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+			+		+						LMX	
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+				+		+	+				LMX	
Libyh/Roulin, Taban	51	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	
Loewenthal , Ron M	19	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		+	+			A2403	LMX	
Martinho, Paiva &		+	+	+	+	+		+		+	+	+	+				+	+				+	CW4,CW6,B13,B27 >	LMX	
McCoy, Heather	18	+	+	+	+	+	+		+	+		+	+											LMX	
Pancoska, Carol Ph	18	+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Permpikul, Vejbaesy	18	+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Pule, Ziningi		+	+	+	+	+	+	+	+	+	+	+	+			+	+		+	+				LMX	
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Rosen-Bronson, Sa		+	+	+	+	+	+	+	+	+	+	+	+			+						+		LMX	
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+						+	+				LMX	
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+									LMX	
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+			+		+					A3,A80	LMX	
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+											LMX	

Table 45. Individual laboratory results for Serum #1192 by Luminex - class I

**** Serum 1192 ****																																								
Investigator	% POS	A30	A31	A33	A34	A43	A1	A26	A29	A36	A3	A80	A74	B7	A66	B42	B55	B67	A11	B81	B56	B82	A6602	A6601	A1101	A1102	B27	B48	B54	B8101	Other	Method								
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+				+					+	+	+	+								LMX					
Bengochea, Carrette	21	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+						+	+	+	+				+				LMX					
Cecka, J. Michael P	65	+	+	+	+	+	+	+	+	+	+	+	+	+	+					+					+	+	+	+								LMX				
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+					+	+	+	+				+	B8201			LMX					
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B2708				LMX				
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+							LMX			
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX		
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX		
Hamdi, Nuha	65	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX		
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+																							LMX	
Libyh/Roulin, Tabar	65	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B8201							LMX	
Loewenthal , Ron M	19	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B60,A32,A68,B8							LMX	
McCoy, Heather	22	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	
Pancoska, Carol Ph	30	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	
Permpikul, Vejbaesy	25	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	
Pule, Ziningi	18	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	
Rosen-Bronson, Sa		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B2708							LMX	
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B60							LMX	
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	

Table 46. Individual laboratory results for Serum #1189-#1192 by Flow Cytometry and ELISA - class I

**** Serum 1189 ****																										
Investigator	% POS	A2	A68	A69	B13	B35	B46	B49	B50	B53	B57	B58	B62	B63	B71	B72	B75	B78	A11	B45	B51	B52	A3	Other	Method	
Eckels/CPMC	95																									FC
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			Elisa
McCoy, Heather	65	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,B48,B44,B27 >		Elisa

**** Serum 1190 ****																										
Investigator	% POS	A2	A68	A69	B13	B18	B35	B37	B44	B45	B57	B58	B59	B63	B65	B72	B78	B27	B51	B53	B62	B64		Other	Method	
Eckels/CPMC	92																									FC
Hahn, Amy B. PhD	92	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				Elisa
McCoy, Heather	56	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		A24,B49,B50,B47 >		Elisa

**** Serum 1191 ****																										
Investigator	% POS	A29	A30	A31	A74	B8																		Other	Method	
Eckels/CPMC	76																									FC
Hahn, Amy B. PhD	76	+	+	+	+	+																		A1,A80		Elisa
McCoy, Heather	30	+	+	+	+	+																		A66,A25,A26,A34 >		Elisa

**** Serum 1192 ****																										
Investigator	% POS	A26	A29	A74																				Other	Method	
Eckels/CPMC	83																									FC
Hahn, Amy B. PhD	83	+	+	+																				A30,A6601		Elisa
McCoy, Heather	28	+	+	+																				A11,A66,B7,B55 >		Elisa

Table 47. Individual laboratory results for Serum #1189-#1190 by C1q and Luminex - class II

Investigator	**** Serum 1189 ****													**** Serum 1190 ****													Other	Method													
	% POS	DQ8	DQ9	DR4											% POS	DP10	DP14	DP17	DP18	DP20	DP28	DP9	DPW2	DPW3	DPW4	DPW6			DR11	DR17	DR18	DR52									
Phelan, Donna L.		+	+	+												+	+	+	+	+	+	+	+	+	+	+	+	+	+												C1q

Investigator	**** Serum 1189 ****													**** Serum 1190 ****													Other	Method																
	% POS	DQ6	DR1	DR4	DR9	DQ4	DQ8	DQ9	DR53	DQ5	DR7	DR14	DR10	DQ7	DQ2	% POS	DP14	DP17	DP18	DP28	DPW2	DPW3	DR11	DR13	DR14	DR52			DR7	DR17	DQ2	DP10	DP20	DP9	DPW6	DR18	DPW4	DP402						
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+			DQA1*01, *03		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX			
Bengochea, Carrett	39	+	+	+	+	+	+	+	+	+				+		29	+	+	+	+	+	+	+	+	+	+	+	+									DR3		LMX					
Cecka, J. Michael F	71	+	+	+	+	+	+	+	+	+						91	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX				
Chen, Dong-Feng F		+	+	+	+	+	+	+	+	+	+			+	DQA1*01, *03		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX				
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	DR15,DR51		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ7		LMX			
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+				DQA1*03:02, *03:01, *04:01, *01:02, *01:03		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX			
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX			
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+							+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX			
Hamdi, Nuha	86	+	+	+	+	+	+	+	+	+				+		38	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX			
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+		DR15,DR51, DQA1*03		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX		
Libyh/Roulin, Tabar	74	+	+	+	+	+	+	+	+	+	+					91	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX	
Pancoska, Carol Ph	38	+	+	+	+	+	+	+	+	+	+					38	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX	
Permpikul, Vejbaes	35	+	+	+	+	+	+	+	+	+	+			+		38	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+							+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX		
Pule, Ziningi	37	+	+	+	+	+					+				DQ3																										LMX			
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+					DQA1*03+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX		
Rosen-Bronson, Sa		+	+	+	+	+	+	+	+	+	+				DQA1*03		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX
Thornton, Alycia		+	+	+	+	+	+	+	+		+				DQA1*03:02, *03:01, *04:01, *01:02, *01:03		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX	
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+		DR15,DR51		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX	
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+				+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX

Table 48. Individual laboratory results for Serum #1191 by C1q and Luminex - class II

**** Serum 1191 ****																								Method		
Investigator	% POS	DP11	DP18	DP19	DP20	DP23	DP28	DPW1	DPW2	DPW3	DPW4	DPW6	DQ2	DQ7	DR11	DR12	DR13	DR14	DR17	DR18	DR52	DR7	DR8	DR9	Other	Method
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			C1q

**** Serum 1191 ****																								Method					
Investigator	% POS	DP17	DP18	DQ7	DR11	DR12	DR13	DR14	DR52	DR7	DR8	DR9	DP28	DR17	DR18	DPW2	DPW4	DP15	DP19	DP20	DP23	DPW3	DP11	DPW1	DP13	DPW6	DQ2	Other	Method
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+									DQA1*04:01, *05:01, DPA1*01:03/*01:04/*01:05, DPA1*03:01	LMX	
Bengochea, Carrett	52	+	+	+	+	+	+	+	+	+	+	+	+			+	+					+					DR3,DR1404	LMX	
Cecka, J. Michael F	100	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+				+	+	+	+	+		LMX	
Chen, Dong-Feng F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	DP402,DP401, DQA1*04,*05,*06, DPA1*01,*03	LMX	
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ4,DQ6,DP402,DP401	LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DPA1*01:03,*03:01,*04:01, DQA1*05:01,*06:01,*04:01	LMX	
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ4	LMX	
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Hamdi, Nuha	97	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ4	LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DP14,DP402,DP401, DQA1*04,*05,*06, DPA1*01	LMX	
Libyh/Roulin, Tabar	97	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+						DQ6,DP402,DP401	LMX	
Pancoska, Carol Ph	49	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ4	LMX	
Permpikul, Vejbaes	41	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DR15,DQ4	LMX	
Pule, Ziningi																												LMX	
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DPA1*01,*03, DQA1*04,*05, DQB1*06:03, *06:09	LMX	
Rosen-Bronson, Sa		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ6, DQA1*04,*05,*06, DPA1*01	LMX	
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DPA1*01:03, *03:01, *04:01, DQA1*05:01, *06:01, *04:01	LMX	
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ5,DQ6	LMX	
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ6	LMX	

Table 49. Individual laboratory results for Serum #1192 by C1q and Luminex - class II

**** Serum 1192 ****																					
Investigator	% POS	DQ7	DQ8	DQ9	DR7															Other	Method
Phelan, Donna L.		+	+	+	+																C1q

**** Serum 1192 ****																											
Investigator	% POS	DR7	DR9	DQ7	DQ8	DQ9	DQ4	DPW1	DPW5	DP19	DP14	DP13	DP9	DP11	DP17	DQ2	DP10	DPW3	DPW6	DR18	DP18	DP401	DPW4	DP15	DP20	Other	Method
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+			+													DQA1*02:01, DPA1*02:02, *02:01	LMX
Bengochea, Carrett	46	+	+	+	+	+	+	+	+	+	+	+			+											DP28	LMX
Cecka, J. Michael F	68	+	+	+	+	+																					LMX
Chen, Dong-Feng F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+									DPA1*02+	LMX
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+							DQA1*02:01,*03:01, *04:01,*06:01, DPA1*02:02,*02:01,*04:01	LMX
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+						LMX
Hahn, Amy B. PhD		+	+	+	+	+	+		+																		LMX
Hamdi, Nuha	71	+	+	+	+	+	+	+	+	+	+	+	+			+		+	+		+						LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		+	+	DPA1*02	LMX
Libyh/Roulin, Tabar	69	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+		+				DR8,DR11,DR13,DR14 >	LMX
Pancoska, Carol Ph	45	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+						LMX
Permpikul, Vejbaes	71	+	+	+	+	+		+													+					DR4,DR11,DR12,DR13 >	LMX
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+						LMX
Pule, Ziningi	43	+	+				+																			DQ3	LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+		+											LMX
Rosen-Bronson, Sa		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+				DPA1*02	LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+			+											DP28	LMX
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	DP23	LMX
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+										LMX

Table 50. Individual laboratory results for Serum #1189-#1192 by NIH, Flow Cytometry, and Other - class II

Investigator	**** Serum 1189 ****										**** Serum 1190 ****										**** Serum 1191 ****										**** Serum 1192 ****										Method
	% POS	DR9								Other	% POS	DR11	DR3							Other	% POS									Other	% POS	DR7						Other			
Claas, F.H.J.		NT									75	+	+									NT																		STD	
Reed, Elaine F. PhD	63	+									71											92																		EXT	
Eckels/CPMC	96										93											99																		FC	

Investigator	**** Serum 1189 ****										**** Serum 1190 ****										**** Serum 1191 ****										**** Serum 1192 ****										Method
	% POS	DQ4	DQ5	DQ6	DQ8	DQ9	DR1	DR4	DR9	Other	% POS	DQ2	DR11	DR12	DR13	DR14	DR17	DR18	DR52	Other	% POS	DQ2	DQ4	DQ7	DR11	DR12	DR13	DR14	DR17	Other	% POS	DQ4	DQ7	DQ8	DQ9	DR7	DR9	Other			
Phelan, Donna L.	89										91										100																			Other	
Reed, Elaine F. PhD	77	+	+	+	+	+	+	+	+		63	+	+	+	+	+	+	+	+		73	+	+	+	+	+	+	+	+	DR7,DR8,DR9,DR18 >	67	+	+	+	+	+	+		Other		

Other = Luminex PRA

NEXT MAILING DATE: March 2, 2016
Arlene Locke, David Gjertson, Qiheng Zhang, and Elaine F. Reed